[8-K] Roivant Sciences Ltd. Reports Material Event

Rhea-AI Filing Summary

Roivant Sciences Ltd. filed a Current Report on Form 8-K stating that on August 11, 2025 the company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.

The filing clarifies that the information in the Item 2.02 section and the attached exhibit is not deemed "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by express reference. The report is signed by Keyur Parekh as Authorized Signatory on August 11, 2025, and identifies the company’s Nasdaq trading symbol as ROIV.

Insights

Financial Analyst

TL;DR: Roivant disclosed a press release with Q2 2025 results via Form 8-K; the filing itself contains the exhibit but no financial figures within the 8-K text.

The 8-K formally attaches a press release reporting financial results for the quarter ended June 30, 2025 (Exhibit 99.1) and includes an Inline XBRL cover page (Exhibit 104). The filing expressly states the Item 2.02 content and exhibit are not "filed" under Section 18 and therefore are not automatically incorporated by reference into other securities filings without explicit reference. From a reporting and disclosure control perspective, this is a routine procedural filing that alerts investors to an earnings release while preserving usual incorporation limitations.

Corporate Governance Expert

TL;DR: The company followed standard Form 8-K procedure to attach an earnings press release and included the required signature and exhibits.

The document identifies the press release as Exhibit 99.1 and the Inline XBRL cover page as Exhibit 104, and includes an authorized signature by Keyur Parekh dated August 11, 2025. The explicit statement that the release is not "filed" under Section 18 is a common legal precaution to limit automatic incorporation by reference. The filing provides the procedural disclosure investors expect when a company issues an earnings release, without additional substantive details in the 8-K itself.

false000163508800016350882025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2025

Roivant Sciences Ltd.

(Exact Name of Registrant as Specified in Charter)

Bermuda	001-40782	98-1173944
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

7th Floor 

50 Broadway

London SW1H 0DB

United Kingdom

(Address of Principal Executive Offices, and Zip Code)

+44 207 400-3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share		ROIV		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2025, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including the exhibit thereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Roivant Science Ltd. Press Release, dated August 11, 2025
104		Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
By:	/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: August 11, 2025

FAQ

What did Roivant (ROIV) file in this 8-K?

The company filed a Current Report on Form 8-K stating it issued a press release announcing financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Does the 8-K include the financial results themselves?

The 8-K attaches the press release as an exhibit but the filing text does not include detailed financial tables or earnings figures.

Is the attached press release considered "filed" under the Exchange Act?

No. The filing states the Item 2.02 information and exhibit are not deemed "filed" under Section 18 and will not be incorporated by reference into other filings except by express reference.

Who signed the Form 8-K for Roivant?

The report is signed by Keyur Parekh, Authorized Signatory, dated August 11, 2025.

What exhibits were included with the 8-K?

Exhibit 99.1 is the Roivant press release dated August 11, 2025, and Exhibit 104 is the Cover Page Interactive Data File (Inline XBRL).